Beximco Pharmaceuticals to strengthen portfolio as interim profit up

(Alliance News) - Beximco Pharmaceuticals Ltd on Tuesday said it aimed to continue momentum into ...

Alliance News 30 January, 2024 | 2:06PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Beximco Pharmaceuticals Ltd on Tuesday said it aimed to continue momentum into the second half as it reported profit and revenue growth for the first financial half.

The Dhaka-based generic pharmaceutical products and active ingredients' manufacturer said pretax profit rose 10% to BDT3.90 billion, around GBP28.1 million, in the six months to December 31 from BDT3.54 billion a year ago.

Net revenue climbed 12% to BDT22.06 billion from BDT19.68 billion. Cost of goods sold increased 13% to BDT12.26 billion from BDT10.81 billion.

Chair Ahmed Rahman said: "Operationally, we have continued to strengthen our portfolio over the period with 15 new product launches in Bangladesh and have received important approvals from the US FDA and the Australian TGA. We look forward to continuing this momentum into the second half of the year."

Beximco shares rose 11% to 38.70 pence each on Tuesday afternoon in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Beximco Pharmaceuticals Ltd DR 32.00 GBX 16.36 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures